Articles tagged "Hepatitis C"

2019 American Transplant Congress
Long-Term Efficacy of Direct-Acting Antiviral Agents
J. Zhang, W. Sun, J. Lin, Y. Tian, L. Ma, L. Zhang, Y. Zhu
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: Long-term efficacy of direct-acting antiviral agents (DAAs) therapy in kidney transplant recipients was unknown. Thus, we aimed to evaluate it in a Chinese cohort…
2019 American Transplant Congress
Ready for Prime Time: Intentional Allocation of Hepatitis C Positive Livers into Hepatitis C Negative Recipients
P. N. Martins¹, B. Movahedi¹, D. Devuni², P. Mahboub¹, A. Bozorgzadeh¹
¹Surgery, Division of Transplantation, University of Massachusets, Worcester, MA, ²Medicine, Division of Hepatology, University of Massachusets, Worcester, MA
*Purpose: The current discrepancy between supply and demand of liver grafts has dramatically increased the waiting time and mortality on the waiting list. The recent…
2019 American Transplant Congress
Trends in Utilization of Deceased Donor Kidneys Based on Donor Hep C Antibody and Nucleic Acid Status
V. Ariyamuthu¹, R. M. LaHoz¹, N. AbdulRahim¹, S. Levea¹, M. MacConmara², C. Hwang², B. Sandikci³, B. Tanriover¹
¹Internal Medicine, UT Southwestern Medical Center, Dallas, TX, ²Surgery, UT Southwestern Medical Center, Dallas, TX, ³University of Chicago Booth School of Business, Chicago, IL
*Purpose: HCV nucleic acid testing (NAT) testing for deceased donors (DD) has been routine since 2015. We intended to look at utilization/discard rates based on…
2019 American Transplant Congress
Excellent Success with Safety and Efficacy of Direct-Acting Anti-Viral HCV Drugs in Kidney Transplant Recipients Using an Evolving Regimen. A Single Institution Experience
A. Sharfuddin, S. A. Hussain, T. Taber, D. Mishler, O. Adebiyi, M. S. Yaqub
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. We…
2019 American Transplant Congress
Preliminary Results from a Multicenter National Trial of Antiviral-Facilitated Transplantation of Hepatitis C Hearts to Expand the Donor Pool
K. Martits-Chalangari, A. K. Doss, M. Clark, J. Felius, S. A. Hall, R. L. Gottlieb
Baylor University Medical Center, Dallas, TX
*Purpose: Solid organs from donors with evidence of active HCV viremia are historically underutilized particularly for HCV negative recipients. The development of easily tolerated, oral,…
2019 American Transplant Congress
Predictors of Glomerular Filtration Rate after Renal Transplantation
O. Andacoglu, Y. Dong, J. Liu, M. Parides, J. Rocca, J. Graham, M. Ajaimy, Y. Azzi, C. Pynadath, L. Liriano-Ward, M. Kinkhabwala, E. Akalin, S. Greenstein
Montefiore Medical Center, Bronx, NY
*Purpose: Glomerular filtration rate (GFR) is an excellent indicator of renal function however there is limited data on the impact of KDPI on long term…
2019 American Transplant Congress
Transplantation of Hepatitis C Virus Positive Donor Kidneys into Hepatitis C Negative Older Recipients
J. A. Graham¹, M. Ajaimy², J. Torabi¹, T. Powell³, J. Weiss⁴, T. Weinstein⁵, S. Greenstein¹, O. Andacoglu¹, A. Campbell⁶, J. Carrero¹, J. Lapponese¹, M. Kinkhabwala¹, E. Akalin², J. P. Rocca¹
¹Surgery, Montefiore Medical Center, Bronx, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Epidemiology and Psychiatry, Montefiore Medical Center, Bronx, NY, ⁴Medical Affairs, Montefiore Medical Center, Bronx, NY, ⁵Risk & Loss Prevention, Montefiore Medical Center, Bronx, NY, ⁶Pharmacy, Montefiore Medical Center, Bronx, NY
*Purpose: Patients awaiting transplantation are often at risk of developing life-threatening disease and complications. Older patients have a disproportionately higher risk of dropping out of…
2019 American Transplant Congress
Reduction in Waitlist Time Using HCV Positive Liver Grafts in HCV Negative Recipients
E. M. Bugeaud, N. Bzowej, J. Hand, J. Scheuermann, H. Bohorquez, C. Brown, D. Bruce, I. Carmody, A. Cohen, S. Joshi, N. Latt, J. Seal, D. Sonnier, G. Therapondos, G. Tyson, N. Girgrah, G. Loss
Ochsner Health System, New Orleans, LA
*Purpose: With direct-acting antiviral (DAA) therapy, we feel that HCV+ organs are safe for all patients regardless of their HCV status and have adopted a…
2019 American Transplant Congress
Impact of Hepatitis C Viremia on Post-Transplant Diabetes Mellitus Development in Liver Transplant Recipients
K. Klein¹, J. Nelson², B. Crowther¹, C. Guerra³, E. Kincaide¹, K. V. Speeg⁴, N. Alkhouri⁵, R. Hall¹
¹University Health System, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, Austin, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX, ²University Health System, San Antonio, TX, ³The University of Texas Health Science Center at San Antonio, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, ⁴University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁵University Health System, The University of Texas Health Science Center at San Antonio, Texas Liver Institute, San Antonio, TX
*Purpose: Compare incidence of post-transplant diabetes mellitus (PTDM) in hepatitis C virus (HCV) patients with and without viremia at the time of orthotopic liver transplantation…
2019 American Transplant Congress
Willingness to Acquire Donor-Derived Hepatitis C Infection May Reduce Waitlist Mortality for Heart Transplant Candidates
B. E. Lonze, A. Reyentovich, N. Moazami, D. E. Smith, C. Gidea, R. A. Montgomery
NYU Langone Transplant Institute, New York, NY
*Purpose: Hearts from deceased donors with hepatitis C infection (HCV+) are disproportionately discarded because most waitlist registrants are HCV negative (HCV-). For some with end-organ…